Blockbuster drugs episode artwork

EPISODE · Nov 9, 2023 · 35 MIN

Blockbuster drugs

from The Bottom Line · host BBC Radio 4

New medicines with sales in the billions of dollars each year are what every pharmaceutical company dreams of, but how do you create one and can they really justify their often high price tags?Evan Davis and guests discuss the changing origins of so-called 'blockbusters' and their importance to the global drug industry, including recent examples like the obesity and diabetes treatments Wegovy and Ozempic, which have made Novo Nordisk one of the richest companies in Europe.Plus, as outright cures for some diseases begin to emerge, how can the pharmaceutical industry and healthcare systems agree on what is a reasonable price to pay for them?Evan is joined by:Sir Patrick Vallance, former president of research and development at GSK, chief scientific advisor to the UK government, now chair of the Natural History Museum; Ruth McKernan, venture partner at SV Health Investors; David Brown, chairman and co-founder of Healx and co-creator of Viagra; Natasha Loder, health editor, The Economist. PRODUCTION TEAM:Producer: Simon Tulett Editor: China Collins Sound: Graham Puddifoot Production co-ordinator: Gemma Ashman(Picture: Rolls of dollar bills next to a bottle of pills. Credit: Getty Images)

Episode metadata supplied by the publisher feed · Published Nov 9, 2023

New medicines with sales in the billions of dollars each year are what every pharmaceutical company dreams of, but how do you create one and can they really justify their often high price tags?Evan Davis and guests discuss the changing origins of so-called 'blockbusters' and their importance to the global drug industry, including recent examples like the obesity and diabetes treatments Wegovy and Ozempic, which have made Novo Nordisk one of the richest companies in Europe.Plus, as outright cures for some diseases begin to emerge, how can the pharmaceutical industry and healthcare systems agree on what is a reasonable price to pay for them?Evan is joined by:Sir Patrick Vallance, former president of research and development at GSK, chief scientific advisor to the UK government, now chair of the Natural History Museum; Ruth McKernan, venture partner at SV Health Investors; David Brown, chairman and co-founder of Healx and co-creator of Viagra; Natasha Loder, health editor, The Economist. PRODUCTION TEAM:Producer: Simon Tulett Editor: China Collins Sound: Graham Puddifoot Production co-ordinator: Gemma Ashman(Picture: Rolls of dollar bills next to a bottle of pills. Credit: Getty Images)

PodParley-generated summary based on available episode metadata and transcript content.

NOW PLAYING

Blockbuster drugs

0:00 35:13

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Bottom Line?

This episode is 35 minutes long.

When was this The Bottom Line episode published?

This episode was published on November 9, 2023.

What is this episode about?

New medicines with sales in the billions of dollars each year are what every pharmaceutical company dreams of, but how do you create one and can they really justify their often high price tags?Evan Davis and guests discuss the changing origins of...

Can I download this The Bottom Line episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!